SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Resident dentists at the University at Buffalo have formed a union with the Union of American Physicians and Dentists.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

In the health care context, patients must agree to pay a hospital’s “regular rates” without knowing exact costs until they ...

Lytus Technologies remains committed to scaling its operations, deepening its presence in emerging markets, and pioneering next-generation technology solutions that redefine industries. With a strong ...

Q2 2025 Earnings Call Transcript February 4, 2025 Premier, Inc. misses on earnings expectations. Reported EPS is $0.25 EPS, ...